Who Owns Phibro Company?

Phibro Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Phibro Animal Health?

Understanding Phibro Animal Health Corporation's ownership is key to grasping its market standing and strategic direction. Since its 2014 IPO, this global animal health and mineral nutrition company, founded in 1946, has been publicly traded.

Tracing its roots back to Phillip Brothers Chemicals, Inc., Phibro has grown significantly. The company, headquartered in Teaneck, New Jersey, now operates in over 95 countries, offering a wide array of products.

Who owns Phibro Animal Health Corporation?

Phibro Animal Health Corporation's ownership structure is a blend of public shareholders and significant institutional investors. The Bendheim family, instrumental in the company's founding and early development, continues to hold influence. For the fiscal year ended June 30, 2024, Phibro reported net sales of $1 billion, with trailing twelve-month revenue reaching $1.19 billion as of March 31, 2025. The company's market capitalization stood at $1.24 billion as of August 15, 2025, reflecting its substantial presence in the animal health sector, which includes products like those detailed in the Phibro PESTEL Analysis.

Phibro Animal Health Corporation's journey began in 1946 as Phillip Brothers Chemicals, Inc. The company's significant expansion into the animal health sector was marked by the 1974 acquisition of Koffolk, an Israeli animal nutrition business. This strategic move laid the groundwork for the entity that would eventually become Phibro Animal Health Corporation, further solidified by acquiring Pfizer Inc.'s global medicated feed additive business in 2000.

Founding Roots

The company's origins trace back to 1946 with the establishment of Phillip Brothers Chemicals, Inc. Its early focus was on the chemical industry before a strategic shift.

Animal Health Pivot

A pivotal moment was the 1974 acquisition of Koffolk, an Israeli animal nutrition business. This acquisition marked the company's significant entry into the animal health market.

Strategic Acquisitions

The company's growth was further propelled by acquiring Pfizer Inc.'s global medicated feed additive business in 2000. This significantly expanded its presence in the animal health sector.

Corporate Identity

In 2003, the company officially changed its name to Phibro Animal Health Corporation. This rebranding solidified its identity as a dedicated animal health company.

Early Backing

Prior to its initial public offering (IPO), Mayflower Limited Partnership, with 3i Group plc as its sole limited partner, was a significant early investor and selling stockholder.

Family Influence

The Bendheim family has played a crucial role in the company's leadership and ownership for many years. Their influence continues to shape the company's direction.

The Bendheim family's enduring influence is a cornerstone of Phibro Animal Health Corporation's ownership structure. Jack C. Bendheim, the current Chairman, President, and CEO, has been at the helm in leadership roles since 1988 and as CEO since March 2014, having served as a director since 1984. His family's investment entity, BFI Co., LLC, holds a commanding 100% of the company's Class B common stock. This dual-class share system, established before the company's 2014 IPO, grants Class B shares ten votes for every one vote of Class A common stock. This structure ensures that Jack C. Bendheim, who has sole voting authority over the shares held by BFI, maintains substantial control over the company's strategic decisions and overall direction. Understanding this ownership dynamic is key to grasping the company's governance and long-term strategy, which is further detailed in articles discussing the Revenue Streams & Business Model of Phibro.

Ownership Control

The Bendheim family, through BFI Co., LLC, exercises significant control over Phibro Animal Health Corporation. This control is primarily managed by Jack C. Bendheim, who holds the sole voting authority for the family's Class B shares.

• 100% of Class B common stock held by BFI Co., LLC.
• Class B shares have ten votes per share, while Class A shares have one vote per share.
• Jack C. Bendheim has sole authority to vote the common stock owned by BFI.
• This structure ensures concentrated voting power and strategic influence within the Bendheim family.

Phibro SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Phibro Animal Health Corporation saw a significant shift with its Initial Public Offering (IPO) on April 11, 2014. This event marked its debut on The NASDAQ Global Market under the ticker symbol 'PAHC,' fundamentally altering its capital raising and public accountability.

Following its IPO, Phibro Animal Health Corporation transitioned to a public entity, with the Bendheim family maintaining significant control through their ownership of Class B common stock. This dual structure allows for public investment while preserving concentrated voting power. As of August 15, 2025, institutional investors represent the largest ownership bloc, with entities like BlackRock, Inc. and Vanguard Group Inc. holding substantial share counts. This broad institutional backing, coupled with the family's continued influence, shapes the company's governance and strategic direction, a dynamic also observed in the Competitors Landscape of Phibro.

Key Stakeholders in Phibro Animal Health

Phibro Animal Health's ownership is characterized by a blend of concentrated family control and widespread institutional investment. Understanding these major shareholders is crucial for assessing the company's direction.

• Bendheim Family: Retains majority voting control through Class B common stock.
• BlackRock, Inc.: A significant institutional investor, holding 3,491,368 shares as of June 30, 2025.
• Vanguard Group Inc.: Another major institutional holder with 1,548,245 shares as of June 30, 2025.
• State Street Corp: Holds 920,190 shares as of March 31, 2025.
• Dimensional Fund Advisors Lp: Owns 557,237 shares as of June 30, 2025.
• Geode Capital Management, Llc: Possesses 554,927 shares as of June 30, 2025.

Phibro PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Phibro Animal Health Corporation is currently chaired by Jack C. Bendheim, who also holds the positions of President and Chief Executive Officer. The board includes his sons, Jonathan Bendheim and Daniel M. Bendheim, in key leadership roles. They are joined by several independent directors, including Sam Gejdenson, E. Thomas Corcoran, Mary Lou Malanoski, Carol A. Wrenn, Alejandro Bernal, and Joyce J. Lee, who joined in January 2025.

Phibro Animal Health Corporation's voting power is significantly influenced by its dual-class share structure. Class A Common Stock, available on Nasdaq, carries one vote per share. In contrast, the non-publicly traded Class B Common Stock grants ten votes per share. The Bendheim family, through BFI Co., LLC, exclusively holds all Class B shares. This arrangement means the Bendheim family, with Jack C. Bendheim having sole voting authority over BFI's shares, maintains majority voting power. This structure classifies Phibro as a 'controlled company' under Nasdaq's governance rules, giving the controlling shareholder substantial influence over corporate decisions, including director elections. This level of control is typical for companies with such a voting structure, and there have been no recent public reports of significant proxy contests or activist investor campaigns impacting Phibro ownership.

Understanding Phibro's Voting Power

Phibro's corporate structure ensures significant control by the founding family. This is primarily achieved through a dual-class share system.

• Class A shares have one vote per share.
• Class B shares have ten votes per share.
• The Bendheim family, via BFI Co., LLC, owns all Class B shares.
• This gives the family majority voting power, impacting Phibro Animal Health ownership.
• Phibro is considered a 'controlled company' by Nasdaq standards.

The concentration of voting power with the Bendheim family is a key aspect of Phibro Animal Health ownership. This structure, detailed in the Brief History of Phibro, ensures continuity in leadership and strategic direction. For investors interested in Phibro Animal Health stock, understanding this voting dynamic is crucial for assessing the influence of major shareholders and the potential impact on Phibro financial performance ownership. The Phibro ownership structure is designed to maintain long-term family involvement, which can be a stabilizing factor for Phibro Animal Health investors.

Phibro Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Phibro Animal Health Corporation has seen a steady increase in institutional investment, indicating growing confidence from major financial entities. While the founding family maintains significant influence, strategic acquisitions have also shaped the company's recent trajectory.

The leadership at Phibro Animal Health Corporation remains consistent, with Jack C. Bendheim serving as Chairman, President, and Chief Executive Officer. His sons, Daniel M. Bendheim and Jonathan Bendheim, also hold important executive and board positions, underscoring the family's continued involvement. Institutional investors have increased their stake in the company, rising from 50.39% to 52.37% as of March 2025. By August 15, 2025, these institutional owners collectively held 25,531,073 shares. This trend reflects a broader pattern in the industry, though the Bendheim family's super-voting Class B shares ensure their strategic control. The company continues its practice of providing quarterly dividends, with a $0.12 per share cash dividend declared in May 2025. There have been no public indications of a planned succession outside the family or any moves towards privatization.

Institutional Investor Growth

Institutional ownership of Phibro Animal Health increased to 52.37% by March 2025. This growing stake highlights increased confidence from large financial entities.

Family Influence and Control

The Bendheim family maintains significant influence through key leadership roles and super-voting Class B shares. This structure ensures continued strategic direction from the founding family.

Strategic Acquisitions

Recent acquisitions, including those in 2019, 2021, and October 2024, have expanded Phibro's product portfolio and market reach. These moves are part of the company's ongoing Growth Strategy of Phibro.

Dividend Payouts

Phibro Animal Health continues to provide regular dividends to its shareholders. A quarterly cash dividend of $0.12 per share was declared in May 2025.

Phibro Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔